<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7279248\results\search\disease\results.xml">
  <result pre="maintenance of cellular homeostasis, and plays a pivotal role in" exact="viral" post="replication processes. In this review, we discuss several aspects"/>
  <result pre="inhibitors endoplasmic stress UPR response 1. Introduction Since December 2019," exact="infection" post="with the severe acute respiratory coronavirus 2 (SARS-CoV-2) has"/>
  <result pre="response 1. Introduction Since December 2019, infection with the severe" exact="acute" post="respiratory coronavirus 2 (SARS-CoV-2) has become a worldwide emergency"/>
  <result pre="1. Introduction Since December 2019, infection with the severe acute" exact="respiratory" post="coronavirus 2 (SARS-CoV-2) has become a worldwide emergency (pandemic)"/>
  <result pre="on a global scale [3,4]. Unfortunately, the symptoms of SARS-CoV-2" exact="infection" post="can vary in an unpredictable manner; there are asymptomatic"/>
  <result pre="are asymptomatic cases as well as patients suffering from pneumonia," exact="acute" post="respiratory distress syndrome and multisystem organ failure [5,6]. Older"/>
  <result pre="asymptomatic cases as well as patients suffering from pneumonia, acute" exact="respiratory" post="distress syndrome and multisystem organ failure [5,6]. Older patients"/>
  <result pre="as well as patients suffering from pneumonia, acute respiratory distress" exact="syndrome" post="and multisystem organ failure [5,6]. Older patients and patients"/>
  <result pre="multisystem organ failure [5,6]. Older patients and patients with preexisting" exact="respiratory" post="or cardiovascular conditions appear to be at the greatest"/>
  <result pre="failure [5,6]. Older patients and patients with preexisting respiratory or" exact="cardiovascular" post="conditions appear to be at the greatest risk for"/>
  <result pre="greatest risk for severe complications and death [6,7]. In the" exact="absence of" post="a proven effective therapy, current management consists of supportive"/>
  <result pre="storm [15], as are antiviral drugs [16]. Nevertheless, in the" exact="absence of" post="long-term and controlled clinical trials, there is no consensus"/>
  <result pre="of drugs to stall the virus attack, followed by blocking" exact="viral" post="replication and, in patients with signs of higher cytokine/chemokine"/>
  <result pre="for the 2003 epidemic started in China (that caused 8000" exact="infections" post="and 800 deaths i.e., a 10% mortality rate), and"/>
  <result pre="the 2012 epidemic that began in Saudi Arabia (causing 2400" exact="infections" post="and 800 deaths i.e., a 35% mortality rate) [19,20]."/>
  <result pre="that the new Coronavirus, SARS-CoV-2 is a Î²-Coronavirus. The SARS-Cov-2" exact="viral" post="genome is complex and resembles that of other coronaviruses."/>
  <result pre="coronaviruses. In particular, 75% of the genome is related to" exact="viral" post="replicase genes from two open reading frames (ORFs), i.e.,"/>
  <result pre="divided into 15 nsps. Proteolytic cleavage is mediated by the" exact="viral" post="proteases nsp3 and nsp5 which, respectively, host a papain-like"/>
  <result pre="papain-like placenta domain and a 3C-like protease domain. Moreover, at" exact="short" post="motifs called transcription-regulatory sequences (TRSs) that are located immediately"/>
  <result pre="(CS) surrounded by variable sequences [21]. Coronaviruses exhibit a round" exact="morphology" post="and are constituted of several components, such as glycoprotein"/>
  <result pre="such as glycoprotein S (Spike), organized in trimers on the" exact="external" post="part of the virion resembling a crown, from which"/>
  <result pre="take their name; this protein determines the virus specificity for" exact="epithelial" post="cells. In fact, it has been suggested that SARS-CoV-2"/>
  <result pre="conversion receptor, ACE2, and CD26 (like SARS-CoV), expressed at both" exact="pulmonary" post="and gastrointestinal levels (thatâ€™s why there are also symptoms"/>
  <result pre="(thatâ€™s why there are also symptoms at these compartments) [22]." exact="Protein" post="M crosses the envelope and interacts within the virion"/>
  <result pre="during the virus release phase inside the host cell. The" exact="Protein" post="E helps protein S attach to the target cells"/>
  <result pre="the target cells membranes. Finally, RNA gives rise to 7" exact="viral" post="proteins and is associated with the N protein, which"/>
  <result pre="indicated significant variations in SARS-CoV and SARS-CoV-2, such as the" exact="absence of" post="protein 8a and the fluctuation in the number of"/>
  <result pre="comprises two subunits, S1 and S2 [27]. S1 determines the" exact="viral" post="host flow rate and cell tropism with the key"/>
  <result pre="repeat 1 (HR1) and 2 (HR2) [28,29]. Starting from the" exact="viral" post="RNA, the synthesis of two 1a/1ab polyproteins (pp1a pp1ab)"/>
  <result pre="RNA, N protein and envelope glycoproteins come together to form" exact="viral" post="bud particles. The vesicles containing virions then merge with"/>
  <result pre="occupied by proline instead of isoleucine [36]. The issue of" exact="viral" post="mutations is the key to explaining potential relapses of"/>
  <result pre="mutation in NSP2 and NSP3 has a role in the" exact="infectious" post="ability and differentiation mechanism of SARS-CoV-2. 2. Currently-Available Therapies"/>
  <result pre="used to cope with this pandemic are mainly based on" exact="symptomatic" post="and respiratory support. On 28 January 2020, the WHO"/>
  <result pre="cope with this pandemic are mainly based on symptomatic and" exact="respiratory" post="support. On 28 January 2020, the WHO published a"/>
  <result pre="Remdesivir has been shown to be most effective in reducing" exact="viral" post="load [38] (GS5734). As an RNA polymerase inhibitor, it"/>
  <result pre="in the fight against SARS-CoV and MERS-CoV, antiviral drugs and" exact="systemic" post="treatment with corticosteroids commonly used previously in clinical practice,"/>
  <result pre="treatment of malaria, and today also in the treatment of" exact="rheumatoid arthritis." post="Several possible mechanisms have been studied. Chloroquine can inhibit"/>
  <result pre="of different viruses [44], with a powerful effect on the" exact="infection" post="and spread of SARS-CoV [45]. Furthermore, chloroquine has immuno-modulatory"/>
  <result pre="worked in both the entry and postentry stages of COVID-19" exact="infection" post="in Vero E6 cells [41]. In Italy, a large"/>
  <result pre="[41]. In Italy, a large survey conducted by the National" exact="Cancer" post="Institute and the Pascale Foundation of Naples focused on"/>
  <result pre="the IL-6 receptor and commonly used in the treatment of" exact="rheumatoid arthritis." post="Passive immunization has been successfully used for the treatment"/>
  <result pre="Passive immunization has been successfully used for the treatment of" exact="infectious diseases," post="and 80 SARS patients were treated with convalescent plasma"/>
  <result pre="important for the maintenance of cellular homeostasis and also in" exact="viral" post="replication processes. The UPS system is a complex process"/>
  <result pre="of proteasome activity by drugs already routinely used in many" exact="tumor" post="pathologies. Some studies have focused on the role played"/>
  <result pre="in the destabilization of antiviral proteins, viruses retain proviral or" exact="viral" post="proteins by manipulating the ubiquitination processes through the expression"/>
  <result pre="activity of a functional UPS. Several studies have shown that" exact="virus infection" post="leads to the accumulation of proteinâ€&quot;ubiquitin conjugates, suggesting an"/>
  <result pre="of a functional UPS. Several studies have shown that virus" exact="infection" post="leads to the accumulation of proteinâ€&quot;ubiquitin conjugates, suggesting an"/>
  <result pre="an important role of the increased ubiquitination process in ubiquitinâ€&quot;proteasome-mediated" exact="viral" post="replication or protein degradation. Furthermore, the accumulation of proteins"/>
  <result pre="reticulum stress and cell death, leading to the inhibition of" exact="viral" post="replication [50,51]. The best-known proteasome inhibitor is Bortezomib (Valcade)"/>
  <result pre="in 2008 as a first-line drug in the treatment of" exact="multiple myeloma." post="Other inhibitors are MG132, Lactacistin, Carfilzomib, Ixazomib and others"/>
  <result pre="COVID-19 [53]. As mentioned, one of the effects of coronavirus" exact="infection" post="is the pro-inflammatory cytokine storm that occurs mainly in"/>
  <result pre="pro-inflammatory cytokine storm that occurs mainly in patients with severe" exact="respiratory" post="conditions. The inhibition of the ubiquitinâ€&quot;proteasome system has proven"/>
  <result pre="the anti-inflammatory effect of UPS inhibition in an airway smooth" exact="muscle" post="(ASM) cell line. Specifically, this study demonstrated that cells"/>
  <result pre="for reversing inflammation and remodeling in a wide variety of" exact="chronic" post="inflammatory conditions [54]. Therefore, overall, the Moutzouris study suggests"/>
  <result pre="a study by Yi Yu et al. concerning the murine" exact="hepatitis" post="virus (MHV-JHM strain, belonging to the Coronaviridae family), it"/>
  <result pre="although MHV can be internalized in the cell in the" exact="absence of" post="a functional ubiquitinâ€&quot;proteasome system, viruses within endosomes or lysosomes"/>
  <result pre="its functional receptor ACE2 [56], is internalized by endocytosis, and" exact="viral" post="RNA is released from the endosome [56,57,58,59]. In the"/>
  <result pre="nonstructural proteins (nsps), including all the nsps of the replicase" exact="viral" post="complex [60,61,62]. Protected by double membrane vesicles (DMV), most"/>
  <result pre="and budding processes in the endoplasmic reticulum of the Golgi" exact="intermediate" post="compartment (ERGIC) [64,65], mature virions are released by exocytosis."/>
  <result pre="RNA and the subsequent protein expression of different CoVs (e.g.," exact="Hepatitis" post="Virus of mouse [MHV], feline infectious peritonitis virus, and"/>
  <result pre="of different CoVs (e.g., Hepatitis Virus of mouse [MHV], feline" exact="infectious" post="peritonitis virus, and severe acute respiratory syndrome CoV) [66]."/>
  <result pre="different CoVs (e.g., Hepatitis Virus of mouse [MHV], feline infectious" exact="peritonitis" post="virus, and severe acute respiratory syndrome CoV) [66]. A"/>
  <result pre="Virus of mouse [MHV], feline infectious peritonitis virus, and severe" exact="acute" post="respiratory syndrome CoV) [66]. A 2010 study by Raaben"/>
  <result pre="of mouse [MHV], feline infectious peritonitis virus, and severe acute" exact="respiratory" post="syndrome CoV) [66]. A 2010 study by Raaben et"/>
  <result pre="mouse [MHV], feline infectious peritonitis virus, and severe acute respiratory" exact="syndrome" post="CoV) [66]. A 2010 study by Raaben et al."/>
  <result pre="cells treated with UPS chemical inhibitors, the synthesis of the" exact="viral" post="CoV RNA and the subsequent protein expression were strongly"/>
  <result pre="particular, the authors attempted to determine whether the inhibition of" exact="virus infection" post="caused by MG132 was specific to this proteasome inhibitor"/>
  <result pre="the authors attempted to determine whether the inhibition of virus" exact="infection" post="caused by MG132 was specific to this proteasome inhibitor"/>
  <result pre="of SARS-CoV by interfering with the early stages of the" exact="viral" post="life cycle, but other inhibitors (e.g., Lactacistin and Bbortezomib)"/>
  <result pre="but other inhibitors (e.g., Lactacistin and Bbortezomib) only marginally affected" exact="viral" post="replication, suggesting that the effect of MG132 is independent"/>
  <result pre="this proteasome inhibitor against COVID-19 [53]. 4. Conclusions In the" exact="absence of" post="definitive protocols, effective antiviral care and a vaccine against"/>
  <result pre="epoxomycin, bortezomib and carfilzomib have the potential to affect both" exact="viral" post="replication as well as pneumonia and acute respiratory distress"/>
  <result pre="the potential to affect both viral replication as well as" exact="pneumonia" post="and acute respiratory distress syndrome. Further studies are now"/>
  <result pre="to affect both viral replication as well as pneumonia and" exact="acute" post="respiratory distress syndrome. Further studies are now warranted in"/>
  <result pre="affect both viral replication as well as pneumonia and acute" exact="respiratory" post="distress syndrome. Further studies are now warranted in order"/>
  <result pre="published version of the manuscript. Funding This research received no" exact="external" post="funding. Conflicts of Interest The authors declare no conflict"/>
  <result pre="health concernLancet202039547047310.1016/S0140-6736(20)30185-931986257 2.GuoY.R.CaoQ.D.HongZ.S.TanY.Y.ChenS.D.JinH.J.TanK.S.WangD.Y.YanY.The origin, transmission and clinical therapies on coronavirus" exact="disease" post="2019 (COVID-19) outbreakâ€&quot;An update on the statusMil. Med. Res.20207101110.1186/s40779-020-00240-032151283"/>
  <result pre="is higher compared to SARS coronavirusJ. Travel Med.20202710.1093/jtm/taaa02132052846 5.ChanJ.F.W.YuanS.KokK.H.ToK.K.W.ChuH.YangJ.XingF.LiuJ.YipC.C.Y.PoonR.W.S.et al.A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
  <result pre="to SARS coronavirusJ. Travel Med.20202710.1093/jtm/taaa02132052846 5.ChanJ.F.W.YuanS.KokK.H.ToK.K.W.ChuH.YangJ.XingF.LiuJ.YipC.C.Y.PoonR.W.S.et al.A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
  <result pre="and pharmacological properties of ozone: The smell of protection in" exact="acute" post="and chronic diseasesInt. J. Mol. Sci.20192063410.3390/ijms2003063430717203 14.ElliE.M.BaratÃ¨C.MendicinoF.PalandriF.PalumboG.A.Mechanisms Underlying the"/>
  <result pre="properties of ozone: The smell of protection in acute and" exact="chronic" post="diseasesInt. J. Mol. Sci.20192063410.3390/ijms2003063430717203 14.ElliE.M.BaratÃ¨C.MendicinoF.PalandriF.PalumboG.A.Mechanisms Underlying the Anti-inflammatory and"/>
  <result pre="anti-inflammatory drugs in the treatment of people with severe coronavirus" exact="disease" post="2019 (COVID-19): The experience of clinical immunologists from ChinaClin."/>
  <result pre="Salud PÃºblica202010.26633/RPSP.2020.40 17.ContiP.RonconiG.CaraffaA.GallengaC.E.RossR.FrydasI.KritasS.K.Induction of pro-inflammatory cytokines (IL-1 and IL-6) and" exact="lung inflammation" post="by COVID-19: Anti-inflammatory strategiesJ. Biol. Regul. Homeost. Agents202010.23812/CONTI-E 18.GalimbertiS.BaldiniC.BarateC.RicciF.BalducciS.GrassiS.FerroF.BudaG.BenedettiE.FazziR.et"/>
  <result pre="20032004Available online: https://www.who.int/csr/sars/country/table2004_04_21/en/(accessed on 19 May 2020) 20.MemishZ.A.PerlmanS.Van KerkhoveM.D.ZumlaA.Middle East" exact="respiratory" post="syndromeLancet20203951063107710.1016/S0140-6736(19)33221-032145185 21.KimD.LeeJ.Y.YangJ.S.KimJ.W.KimV.N.ChangH.The Architecture of SARS-CoV-2 TranscriptomeCell202010.1016/j.cell.2020.04.011 22.YanR.ZhangY.LiY.XiaL.GuoY.ZhouQ.Structural basis for"/>
  <result pre="Capture-Based Next-Generation SequencingmSphere202010.1128/mSphere.00807-1931996413 25.WuF.ZhaoS.YuB.ChenY.M.WangW.SongZ.G.HuY.TaoZ.W.TianJ.H.PeiY.Y.et al.A new coronavirus associated with human" exact="respiratory" post="disease in ChinaNature202010.1038/s41586-020-2008-332015508 26.De WitE.Van DoremalenN.FalzaranoD.MunsterV.J.SARS and MERS: Recent"/>
  <result pre="Next-Generation SequencingmSphere202010.1128/mSphere.00807-1931996413 25.WuF.ZhaoS.YuB.ChenY.M.WangW.SongZ.G.HuY.TaoZ.W.TianJ.H.PeiY.Y.et al.A new coronavirus associated with human respiratory" exact="disease" post="in ChinaNature202010.1038/s41586-020-2008-332015508 26.De WitE.Van DoremalenN.FalzaranoD.MunsterV.J.SARS and MERS: Recent insights"/>
  <result pre="in spike proteinCell. Mol. Immunol.20201310.1038/s41423-020-0374-231611651 29.YuF.DuL.OjciusD.M.PanC.JiangS.Measures for diagnosing and treating" exact="infections" post="by a novel coronavirus responsible for a pneumonia outbreak"/>
  <result pre="and treating infections by a novel coronavirus responsible for a" exact="pneumonia" post="outbreak originating in Wuhan, ChinaMicrobes Infect.202010.1016/j.micinf.2020.01.003 30.CascellaM.RajnikM.CuomoA.DulebohnS.C.Di NapoliR.Features, Evaluation"/>
  <result pre="of Novel Subgenomic RNAs and Noncanonical Transcription Initiation Signals of" exact="Severe" post="Acute Respiratory Syndrome CoronavirusJ. Virol.200510.1128/JVI.79.9.5288-5295.2005 32.PerrierA.BonninA.DesmaretsL.DanneelsA.GoffardA.RouillÃ©Y.DubuissonJ.BelouzardS.The C-terminal domain of"/>
  <result pre="Novel Subgenomic RNAs and Noncanonical Transcription Initiation Signals of Severe" exact="Acute" post="Respiratory Syndrome CoronavirusJ. Virol.200510.1128/JVI.79.9.5288-5295.2005 32.PerrierA.BonninA.DesmaretsL.DanneelsA.GoffardA.RouillÃ©Y.DubuissonJ.BelouzardS.The C-terminal domain of the"/>
  <result pre="Subgenomic RNAs and Noncanonical Transcription Initiation Signals of Severe Acute" exact="Respiratory" post="Syndrome CoronavirusJ. Virol.200510.1128/JVI.79.9.5288-5295.2005 32.PerrierA.BonninA.DesmaretsL.DanneelsA.GoffardA.RouillÃ©Y.DubuissonJ.BelouzardS.The C-terminal domain of the MERS"/>
  <result pre="RNAs and Noncanonical Transcription Initiation Signals of Severe Acute Respiratory" exact="Syndrome" post="CoronavirusJ. Virol.200510.1128/JVI.79.9.5288-5295.2005 32.PerrierA.BonninA.DesmaretsL.DanneelsA.GoffardA.RouillÃ©Y.DubuissonJ.BelouzardS.The C-terminal domain of the MERS coronavirusMprotein"/>
  <result pre="the Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long" exact="Structural" post="Studies of SARS CoronavirusJ. Virol.202010.1128/JVI.00127-2031996437 35.LetkoM.MarziA.MunsterV.Functional assessment of cell"/>
  <result pre="nsp2 and nsp3 in its pathogenesisJ. Med. Virol.202010.1002/jmv.25719 38.AgostiniM.L.AndresE.L.SimsA.C.GrahamR.L.SheahanT.P.LuX.SmithE.C.CaseJ.B.FengJ.Y.JordanR.et al.Coronavirus" exact="susceptibility to" post="the antiviral remdesivir (GS-5734) is mediated by the viral"/>
  <result pre="susceptibility to the antiviral remdesivir (GS-5734) is mediated by the" exact="viral" post="polymerase and the proofreading exoribonucleaseMBio201810.1128/mBio.00221-18 39.SheahanT.P.SimsA.C.LeistS.R.SchÃ¤ferA.WonJ.BrownA.J.MontgomeryS.A.HoggA.BabusisD.ClarkeM.O.et al.Comparative therapeutic efficacy"/>
  <result pre="al.Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected" exact="Pneumonia" post="in Wuhan, ChinaJAMA J. Am. Med. Assoc.202010.1001/jama.2020.1585 43.LiH.WangY.M.XuJ.Y.CaoB.Potential antiviral"/>
  <result pre="He He Hu Xi Za Zhi202010.3760/cma.j.issn.1001-0939.2020.03.004 44.SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of chloroquine on" exact="viral" post="infections: An old drug against todayâ€™s diseases?Lancet Infect. Dis.2003372272710.1016/S1473-3099(03)00806-514592603"/>
  <result pre="Infect. Dis.2003372272710.1016/S1473-3099(03)00806-514592603 45.VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol. J.200510.1186/1743-422X-2-6916115318 46.Casorla-PÃ©rezL.A.LÃ³pezT.LÃ³pezS.AriasC.F.The Ubiquitin-Proteasome System Is Necessary for"/>
  <result pre="Is Necessary for Efficient Replication of Human AstrovirusJ. Virol.201710.1128/JVI.01809-1729093085 47.SchneiderM.AckermannK.StuartM.WexC.ProtzerU.SchÃ¤tzlH.M.GilchS.Severe" exact="Acute" post="Respiratory Syndrome Coronavirus Replication Is Severely Impaired by MG132"/>
  <result pre="Necessary for Efficient Replication of Human AstrovirusJ. Virol.201710.1128/JVI.01809-1729093085 47.SchneiderM.AckermannK.StuartM.WexC.ProtzerU.SchÃ¤tzlH.M.GilchS.Severe Acute" exact="Respiratory" post="Syndrome Coronavirus Replication Is Severely Impaired by MG132 due"/>
  <result pre="for Efficient Replication of Human AstrovirusJ. Virol.201710.1128/JVI.01809-1729093085 47.SchneiderM.AckermannK.StuartM.WexC.ProtzerU.SchÃ¤tzlH.M.GilchS.Severe Acute Respiratory" exact="Syndrome" post="Coronavirus Replication Is Severely Impaired by MG132 due to"/>
  <result pre="to Proteasome-Independent Inhibition of M-CalpainJ. Virol.201210.1128/JVI.01001-12 48.BarrettoN.JuknelieneD.RatiaK.ChenZ.MesecarA.D.BakerS.C.The Papain-Like Protease of" exact="Severe" post="Acute Respiratory Syndrome Coronavirus Has Deubiquitinating ActivityJ. Virol.200510.1128/JVI.79.24.15189-15198.2005 49.LindnerH.A.Fotouhi-ArdakaniN.LytvynV.LachanceP.SuleaT.MenardR.The"/>
  <result pre="Proteasome-Independent Inhibition of M-CalpainJ. Virol.201210.1128/JVI.01001-12 48.BarrettoN.JuknelieneD.RatiaK.ChenZ.MesecarA.D.BakerS.C.The Papain-Like Protease of Severe" exact="Acute" post="Respiratory Syndrome Coronavirus Has Deubiquitinating ActivityJ. Virol.200510.1128/JVI.79.24.15189-15198.2005 49.LindnerH.A.Fotouhi-ArdakaniN.LytvynV.LachanceP.SuleaT.MenardR.The Papain-Like"/>
  <result pre="Inhibition of M-CalpainJ. Virol.201210.1128/JVI.01001-12 48.BarrettoN.JuknelieneD.RatiaK.ChenZ.MesecarA.D.BakerS.C.The Papain-Like Protease of Severe Acute" exact="Respiratory" post="Syndrome Coronavirus Has Deubiquitinating ActivityJ. Virol.200510.1128/JVI.79.24.15189-15198.2005 49.LindnerH.A.Fotouhi-ArdakaniN.LytvynV.LachanceP.SuleaT.MenardR.The Papain-Like Protease"/>
  <result pre="of M-CalpainJ. Virol.201210.1128/JVI.01001-12 48.BarrettoN.JuknelieneD.RatiaK.ChenZ.MesecarA.D.BakerS.C.The Papain-Like Protease of Severe Acute Respiratory" exact="Syndrome" post="Coronavirus Has Deubiquitinating ActivityJ. Virol.200510.1128/JVI.79.24.15189-15198.2005 49.LindnerH.A.Fotouhi-ArdakaniN.LytvynV.LachanceP.SuleaT.MenardR.The Papain-Like Protease from"/>
  <result pre="Coronavirus Has Deubiquitinating ActivityJ. Virol.200510.1128/JVI.79.24.15189-15198.2005 49.LindnerH.A.Fotouhi-ArdakaniN.LytvynV.LachanceP.SuleaT.MenardR.The Papain-Like Protease from the" exact="Severe" post="Acute Respiratory Syndrome Coronavirus Is a Deubiquitinating EnzymeJ. Virol.200510.1128/JVI.79.24.15199-15208.2005"/>
  <result pre="Has Deubiquitinating ActivityJ. Virol.200510.1128/JVI.79.24.15189-15198.2005 49.LindnerH.A.Fotouhi-ArdakaniN.LytvynV.LachanceP.SuleaT.MenardR.The Papain-Like Protease from the Severe" exact="Acute" post="Respiratory Syndrome Coronavirus Is a Deubiquitinating EnzymeJ. Virol.200510.1128/JVI.79.24.15199-15208.2005 50.TibulloD.BarbagalloI.GiallongoC.VanellaL.ConticelloC.RomanoA.SacconeS.GodosJ.Di"/>
  <result pre="Deubiquitinating ActivityJ. Virol.200510.1128/JVI.79.24.15189-15198.2005 49.LindnerH.A.Fotouhi-ArdakaniN.LytvynV.LachanceP.SuleaT.MenardR.The Papain-Like Protease from the Severe Acute" exact="Respiratory" post="Syndrome Coronavirus Is a Deubiquitinating EnzymeJ. Virol.200510.1128/JVI.79.24.15199-15208.2005 50.TibulloD.BarbagalloI.GiallongoC.VanellaL.ConticelloC.RomanoA.SacconeS.GodosJ.Di RaimondoF.Li"/>
  <result pre="ActivityJ. Virol.200510.1128/JVI.79.24.15189-15198.2005 49.LindnerH.A.Fotouhi-ArdakaniN.LytvynV.LachanceP.SuleaT.MenardR.The Papain-Like Protease from the Severe Acute Respiratory" exact="Syndrome" post="Coronavirus Is a Deubiquitinating EnzymeJ. Virol.200510.1128/JVI.79.24.15199-15208.2005 50.TibulloD.BarbagalloI.GiallongoC.VanellaL.ConticelloC.RomanoA.SacconeS.GodosJ.Di RaimondoF.Li VoltiG.Heme"/>
  <result pre="nuclear translocation regulates bortezomibinduced cytotoxicity and mediates genomic instability in" exact="myeloma" post="cellsOncotarget201610.18632/oncotarget.7563 51.GaoG.LuoH.The ubiquitin-proteasome pathway in viral infectionsCan. J. Physiol."/>
  <result pre="mediates genomic instability in myeloma cellsOncotarget201610.18632/oncotarget.7563 51.GaoG.LuoH.The ubiquitin-proteasome pathway in" exact="viral" post="infectionsCan. J. Physiol. Pharmacol.20068451410.1139/y05-14416845885 52.TibulloD.LongoA.VicarioN.RomanoA.BarbatoA.RosaM.D.BarbagalloI.AnfusoC.D.LupoG.GulinoR.et al.Ixazomib improves bone remodeling"/>
  <result pre="bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by" exact="myeloma" post="cellsCancers20201232310.3390/cancers12020323 53.WangJ.Fast Identification of Possible Drug Treatment of Coronavirus"/>
  <result pre="myeloma cellsCancers20201232310.3390/cancers12020323 53.WangJ.Fast Identification of Possible Drug Treatment of Coronavirus" exact="Disease" post="-19 (COVID-19) Through Computational Drug Repurposing StudyJ. Chem. Inf."/>
  <result pre="Endosome to Cytoplasm during Virus EntryJ. Virol.200510.1128/JVI.79.1.644-648.200515596861 56.InoueY.TanakaN.TanakaY.InoueS.MoritaK.ZhuangM.HattoriT.SugamuraK.Clathrin-Dependent Entry of" exact="Severe" post="Acute Respiratory Syndrome Coronavirus into Target Cells Expressing ACE2"/>
  <result pre="to Cytoplasm during Virus EntryJ. Virol.200510.1128/JVI.79.1.644-648.200515596861 56.InoueY.TanakaN.TanakaY.InoueS.MoritaK.ZhuangM.HattoriT.SugamuraK.Clathrin-Dependent Entry of Severe" exact="Acute" post="Respiratory Syndrome Coronavirus into Target Cells Expressing ACE2 with"/>
  <result pre="Cytoplasm during Virus EntryJ. Virol.200510.1128/JVI.79.1.644-648.200515596861 56.InoueY.TanakaN.TanakaY.InoueS.MoritaK.ZhuangM.HattoriT.SugamuraK.Clathrin-Dependent Entry of Severe Acute" exact="Respiratory" post="Syndrome Coronavirus into Target Cells Expressing ACE2 with the"/>
  <result pre="during Virus EntryJ. Virol.200510.1128/JVI.79.1.644-648.200515596861 56.InoueY.TanakaN.TanakaY.InoueS.MoritaK.ZhuangM.HattoriT.SugamuraK.Clathrin-Dependent Entry of Severe Acute Respiratory" exact="Syndrome" post="Coronavirus into Target Cells Expressing ACE2 with the Cytoplasmic"/>
  <result pre="protein together with virus receptor ACE2Virus Res.200810.1016/j.virusres.2008.03.004 59.YangZ.-Y.HuangY.GaneshL.LeungK.KongW.-P.SchwartzO.SubbaraoK.NabelG.J.pH-Dependent Entry of" exact="Severe" post="Acute Respiratory Syndrome Coronavirus Is Mediated by the Spike"/>
  <result pre="together with virus receptor ACE2Virus Res.200810.1016/j.virusres.2008.03.004 59.YangZ.-Y.HuangY.GaneshL.LeungK.KongW.-P.SchwartzO.SubbaraoK.NabelG.J.pH-Dependent Entry of Severe" exact="Acute" post="Respiratory Syndrome Coronavirus Is Mediated by the Spike Glycoprotein"/>
  <result pre="with virus receptor ACE2Virus Res.200810.1016/j.virusres.2008.03.004 59.YangZ.-Y.HuangY.GaneshL.LeungK.KongW.-P.SchwartzO.SubbaraoK.NabelG.J.pH-Dependent Entry of Severe Acute" exact="Respiratory" post="Syndrome Coronavirus Is Mediated by the Spike Glycoprotein and"/>
  <result pre="virus receptor ACE2Virus Res.200810.1016/j.virusres.2008.03.004 59.YangZ.-Y.HuangY.GaneshL.LeungK.KongW.-P.SchwartzO.SubbaraoK.NabelG.J.pH-Dependent Entry of Severe Acute Respiratory" exact="Syndrome" post="Coronavirus Is Mediated by the Spike Glycoprotein and Enhanced"/>
  <result pre="Coronavirus Is Mediated by the Spike Glycoprotein and Enhanced by" exact="Dendritic Cell" post="Transfer through DC-SIGNJ. Virol.200410.1128/JVI.78.11.5642-5650.2004 60.SatijaN.LalS.K.The molecular biology of SARS"/>
  <result pre="of SARS coronavirusAnn. N. Y. Acad. Sci.20071102263810.1196/annals.1408.00217470909 61.TanY.J.LimS.G.HongW.Understanding the accessory" exact="viral" post="proteins unique to the severe acute respiratory syndrome (SARS)"/>
  <result pre="Sci.20071102263810.1196/annals.1408.00217470909 61.TanY.J.LimS.G.HongW.Understanding the accessory viral proteins unique to the severe" exact="acute" post="respiratory syndrome (SARS) coronavirusAntivir. Res.200672788810.1016/j.antiviral.2006.05.01016820226 62.ThielV.IvanovK.A.PuticsÃ�.HertzigT.SchelleB.BayerS.WeiÃŸbrichB.SnijderE.J.RabenauH.DoerrH.W.et al.Mechanisms and enzymes"/>
  <result pre="61.TanY.J.LimS.G.HongW.Understanding the accessory viral proteins unique to the severe acute" exact="respiratory" post="syndrome (SARS) coronavirusAntivir. Res.200672788810.1016/j.antiviral.2006.05.01016820226 62.ThielV.IvanovK.A.PuticsÃ�.HertzigT.SchelleB.BayerS.WeiÃŸbrichB.SnijderE.J.RabenauH.DoerrH.W.et al.Mechanisms and enzymes involved"/>
  <result pre="the accessory viral proteins unique to the severe acute respiratory" exact="syndrome" post="(SARS) coronavirusAntivir. Res.200672788810.1016/j.antiviral.2006.05.01016820226 62.ThielV.IvanovK.A.PuticsÃ�.HertzigT.SchelleB.BayerS.WeiÃŸbrichB.SnijderE.J.RabenauH.DoerrH.W.et al.Mechanisms and enzymes involved in"/>
  <result pre="der MeulenJ.KoertenH.K.MommaasA.M.Ultrastructure and Origin of Membrane Vesicles Associated with the" exact="Severe" post="Acute Respiratory Syndrome Coronavirus Replication ComplexJ. Virol.200610.1128/JVI.02501-05 64.KlumpermanJ.LockerJ.K.MeijerA.HorzinekM.C.GeuzeH.J.RottierP.J.Coronavirus M"/>
  <result pre="MeulenJ.KoertenH.K.MommaasA.M.Ultrastructure and Origin of Membrane Vesicles Associated with the Severe" exact="Acute" post="Respiratory Syndrome Coronavirus Replication ComplexJ. Virol.200610.1128/JVI.02501-05 64.KlumpermanJ.LockerJ.K.MeijerA.HorzinekM.C.GeuzeH.J.RottierP.J.Coronavirus M proteins"/>
  <result pre="and Origin of Membrane Vesicles Associated with the Severe Acute" exact="Respiratory" post="Syndrome Coronavirus Replication ComplexJ. Virol.200610.1128/JVI.02501-05 64.KlumpermanJ.LockerJ.K.MeijerA.HorzinekM.C.GeuzeH.J.RottierP.J.Coronavirus M proteins accumulate"/>
  <result pre="Origin of Membrane Vesicles Associated with the Severe Acute Respiratory" exact="Syndrome" post="Coronavirus Replication ComplexJ. Virol.200610.1128/JVI.02501-05 64.KlumpermanJ.LockerJ.K.MeijerA.HorzinekM.C.GeuzeH.J.RottierP.J.Coronavirus M proteins accumulate in"/>
  <result pre="Plays an Important Role during Various Stages of the Coronavirus" exact="Infection" post="CycleJ. Virol.201010.1128/JVI.00485-1020484504 67.KisselevA.F.GoldbergA.L.Proteasome inhibitors: From research tools to drug"/>
 </snippets>
</snippetsTree>
